Literature DB >> 19652050

High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide.

Derrick Soong, Reem Haj, Mova G Leung, Robert Myers, Brian Higgins, Jeff Myers, Sudha Rajagopal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19652050     DOI： 10.1200/JCO.2009.23.0508

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  15 in total

1.  Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study.

Authors:  D Rayson; S Lutes; M Sellon; B Colwell; M Dorreen; A Drucker; A Jeyakumar; S Snow; T Younis
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

Review 2.  Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials.

Authors:  Orit Freedman; Eitan Amir; Camilla Zimmermann; Mark Clemons
Journal:  Support Care Cancer       Date:  2011-01-04       Impact factor: 3.603

3.  Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity.

Authors:  Gabrielle Rocque; Adedayo Onitilo; Jessica Engel; Erica Pettke; Alice Boshoven; Kyungmann Kim; Shailly Rishi; Bonnie Waack; Kari B Wisinski; Amye Tevaarwerk; Mark E Burkard
Journal:  Breast Cancer Res Treat       Date:  2011-11-08       Impact factor: 4.872

4.  Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC).

Authors:  Mark Clemons; Sasha Mazzarello; John Hilton; Anil Joy; Julie Price-Hiller; Xiaofu Zhu; Shailendra Verma; Anne Kehoe; Mohammed Fk Ibrahim; Marta Sienkiewicz; Carol Stober; Lisa Vandermeer; Brian Hutton; Ranjeeta Mallick; Dean Fergusson
Journal:  Support Care Cancer       Date:  2018-08-11       Impact factor: 3.603

5.  Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres.

Authors:  Y Madarnas; S F Dent; S F Husain; A Robinson; S Alkhayyat; W M Hopman; J L Verreault; T Vandenberg
Journal:  Curr Oncol       Date:  2011-06       Impact factor: 3.677

6.  Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy.

Authors:  Alexandre Chan; Wing Hang Fu; Vivianne Shih; Jurja Chua Coyuco; Sze Huey Tan; Raymond Ng
Journal:  Support Care Cancer       Date:  2010-03-17       Impact factor: 3.603

7.  Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy-single-centre experience.

Authors:  X Zhu; N Bouganim; L Vandermeer; S F Dent; G Dranitsaris; M J Clemons
Journal:  Curr Oncol       Date:  2012-08       Impact factor: 3.677

8.  Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.

Authors:  Mark E Burkard; Kari B Wisinski; Uchenna O Njiaju; Sarahmaria Donohue; Robert Hegeman; Amy Stella; Patrick Mansky; Varsha Shah; Timothy Goggins; Rubina Qamar; Leah Dietrich; Kyungmann Kim; Anne M Traynor; Amye J Tevaarwerk
Journal:  Clin Breast Cancer       Date:  2013-10-26       Impact factor: 3.225

9.  Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia.

Authors:  A K Altwairgi; W M Hopman; M Mates
Journal:  Curr Oncol       Date:  2013-06       Impact factor: 3.677

Review 10.  Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic.

Authors:  Geralyn E Waters; Patricia Corrigan; Mandy Gatesman; Thomas J Smith
Journal:  J Oncol Pract       Date:  2012-11-06       Impact factor: 3.840
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.